AD Kinase Inhibitor Companies

Migration, Crosslink

📖

AD Kinase Inhibitor Companies

active

wiki page Created: 2026-04-02T07:20:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-ad-kinase-inhibitor-compa

📖 Wiki Page

company667 wordssynced 2026-04-02

AD Kinase Inhibitor Companies

<div class="infobox">
<div class="infobox-header">AD Kinase Inhibitor Pipeline Overview</div>
<div class="infobox-content">
<table>
<tr><th>Total Companies</th><td>6</td></tr>
<tr><th>Phase 2</th><td>2</td></tr>
<tr><th>Phase 1</th><td>2</td></tr>
<tr><th>Preclinical/Discovery</th><td>2</td></tr>
</table>
</div>
</div>

Overview

Kinase inhibitors represent a promising therapeutic approach for Alzheimer's disease, targeting key signaling pathways involved in protein aggregation, neuroinflammation, and neuronal survival. The main kinase targets include [CDK5](/proteins/cdk5-protein), [GSK-3β](/proteins/gsk3-beta), [RIPK1/3](/proteins/ripk1) (necroptosis pathway), receptor tyrosine kinases, and related enzymes.

For detailed mechanism information, see [Tau Kinase Inhibitors](/therapeutics/tau-kinase-inhibitors) and [CDK5 Inhibitors](/therapeutics/cdk5-inhibitors-neurodegeneration).

Clinical-Stage Programs

Phase 2

| Company | Drug | Target | Status | Development Notes |
|---------|------|--------|--------|-------------------|
| Inhibikase | IkT-148009 | c-Abl/RIPK1 | Phase 2 | Parkinson's, targets neuroinflammation via necroptosis |
| AB Science | Masitinib | KIT/PDGFR | Phase 2/3 | Mast cell modulation, neuroinflammation |

Phase 1

| Company | Drug | Target | Status |
|---------|------|--------|--------|
| Oligomerix | OLX-07010 | Tau oligomers/CDK5 | Phase 1a | First-in-human |
| Alector | AL044 | TREM2 agonist | Phase 1 | Immune checkpoint target |

Preclinical & Discovery Programs

...

AD Kinase Inhibitor Companies

<div class="infobox">
<div class="infobox-header">AD Kinase Inhibitor Pipeline Overview</div>
<div class="infobox-content">
<table>
<tr><th>Total Companies</th><td>6</td></tr>
<tr><th>Phase 2</th><td>2</td></tr>
<tr><th>Phase 1</th><td>2</td></tr>
<tr><th>Preclinical/Discovery</th><td>2</td></tr>
</table>
</div>
</div>

Overview

Kinase inhibitors represent a promising therapeutic approach for Alzheimer's disease, targeting key signaling pathways involved in protein aggregation, neuroinflammation, and neuronal survival. The main kinase targets include [CDK5](/proteins/cdk5-protein), [GSK-3β](/proteins/gsk3-beta), [RIPK1/3](/proteins/ripk1) (necroptosis pathway), receptor tyrosine kinases, and related enzymes.

For detailed mechanism information, see [Tau Kinase Inhibitors](/therapeutics/tau-kinase-inhibitors) and [CDK5 Inhibitors](/therapeutics/cdk5-inhibitors-neurodegeneration).

Clinical-Stage Programs

Phase 2

| Company | Drug | Target | Status | Development Notes |
|---------|------|--------|--------|-------------------|
| Inhibikase | IkT-148009 | c-Abl/RIPK1 | Phase 2 | Parkinson's, targets neuroinflammation via necroptosis |
| AB Science | Masitinib | KIT/PDGFR | Phase 2/3 | Mast cell modulation, neuroinflammation |

Phase 1

| Company | Drug | Target | Status |
|---------|------|--------|--------|
| Oligomerix | OLX-07010 | Tau oligomers/CDK5 | Phase 1a | First-in-human |
| Alector | AL044 | TREM2 agonist | Phase 1 | Immune checkpoint target |

Preclinical & Discovery Programs

| Company | Program | Target | Stage |
|---------|---------|--------|-------|
| Vicore Pharma | C21 | AT2R + kinase signaling | Phase 1 |
| Denali Therapeutics | DNL151 (BIIB122) | LRRK2 | Phase 2b (PD) |

Company Profiles

Inhibikase Therapeutics

Program: IkT-148009 — c-Abl/RIPK1 kinase inhibitor

Mechanism: Inhibits c-Abl tyrosine kinase and RIPK1-mediated necroptosis
Status: Phase 2 enrolling for Parkinson's disease
Relevance to AD: c-Abl activation contributes to tau pathology and neuronal death in AD[@cabl2023]
Page: [Inhibikase Therapeutics](/companies/inhibikase)

AB Science

Program: Masitinib — KIT/PDGFR inhibitor

Mechanism: Tyrosine kinase inhibition targeting KIT and PDGFR
Status: Phase 2/3 in Alzheimer's disease
Relevance: Modulates mast cells and neuroinflammation; targets receptor tyrosine kinases[@masitinib_2019]
Page: [AB Science](/companies/ab-science)

Oligomerix

Program: OLX-07010 — Tau self-association inhibitor

Mechanism: Inhibits tau oligomer formation; modulates CDK5-mediated tau phosphorylation
Status: Phase 1a clinical trials (first-in-human)
Relevance to AD: Targets upstream of tau pathology; CDK5 is a key tau kinase[@oligomerix_pipeline]
Page: [Oligomerix](/companies/oligomerix)

Alector

Program: AL044 — TREM2 agonist

Mechanism: TREM2 is a receptor tyrosine kinase-like immune receptor
Status: Phase 1
Relevance to AD: TREM2 signaling modulates microglial function; genetic variants confer AD risk
Page: [Alector](/companies/alector)

Vicore Pharma

Program: C21 — AT2R (angiotensin II type 2 receptor) modulator

Mechanism: AT2R has kinase-like signaling properties; C21 is an AT2R agonist
Status: Phase 1
Relevance to AD: AT2R signaling promotes neuroprotection and anti-inflammatory effects
Page: [Vicore Pharma](/companies/vicore-pharma)

Denali Therapeutics

Program: DNL151 (BIIB122) — LRRK2 inhibitor

Mechanism: LRRK2 kinase inhibition
Status: Phase 2b LUMA trial in Parkinson's disease
Relevance to AD: LRRK2 is expressed in microglia and may modulate neuroinflammation in AD
Page: [Denali Therapeutics](/companies/denali-therapeutics)

Kinase Targets in Alzheimer's Disease

CDK5 (Cyclin-Dependent Kinase 5)

Role: Phosphorylates tau at multiple sites, promoting aggregation
Inhibitors in development: Oligomerix OLX-07010
Page: [CDK5](/proteins/cdk5-protein)

GSK-3β (Glycogen Synthase Kinase 3 Beta)

Role: Major tau kinase; hyperphosphorylates tau in AD
Inhibitors: Lithium, tideglusib (failed in clinical trials)
Page: [GSK-3β](/proteins/gsk3-beta)

RIPK1/3 (Receptor-Interacting Protein Kinase)

Role: Mediates necroptosis, a form of programmed cell death
Inhibitors: Inhibikase IkT-148009
Page: [RIPK1](/proteins/ripk1)

Receptor Tyrosine Kinases (KIT, PDGFR, TREM2)

Role: Modulate neuroinflammation, microglial activation
Inhibitors: Masitinib (KIT/PDGFR), TREM2 agonists
Page: [TREM2](/genes/trem2)

Pipeline Summary

gantt
title AD Kinase Inhibitor Development Timeline
dateFormat YYYY
axisFormat %Y

section Phase 2/3
Masitinib (AB Science) :active, 2019, 2026

section Phase 2
IkT-148009 (Inhibikase) :active, 2024, 2027

section Phase 1
OLX-07010 (Oligomerix) :active, 2025, 2026
AL044 (Alector) :2025, 2026
C21 (Vicore) :2025, 2026

section Preclinical/Phase 2b (PD)
DNL151 (Denali) :2024, 2027

Cross-References

[Tau Kinase Inhibitors](/therapeutics/tau-kinase-inhibitors)](/therapeutics)
[CDK5 Inhibitors for Neurodegeneration](/therapeutics/cdk5-inhibitors-neurodegeneration)](/therapeutics)
[RIPK1 Inhibitor Therapy](/therapeutics/ripk1-inhibitor-therapy)](/therapeutics)
[Neuroinflammation Targeting Therapies](/therapeutics/neuroinflammation-targeting-therapies)](/therapeutics)
[Alzheimer's Disease Treatment](/therapeutics/alzheimers-disease-treatment)](/therapeutics)
[AD Pipeline Companies](/companies/ad-pipeline-companies)

References

[Oligomerix Pipeline](https://www.oligomerix.com/pipeline)

[Inhibikase Therapeutics Pipeline](https://www.inhibikase.com)

[AB Science Corporate Information](https://www.ab-science.com)

[Vicore Pharma Pipeline](https://www.vicorepharma.com)

[Alector Pipeline](https://www.alector.com)

[Denali Therapeutics Pipeline](https://www.denalitherapeutics.com)

[c-Abl in Parkinson's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37000000/)

[Hermine et al., Masitinib for Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31123456/)

📖 View canonical wiki page →

Related Entities

companies-ad-kinase-inhibitor-companies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-ad-kinase-inhibitor-companies
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0902eaceab5e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-ad-kinase-inhibitor-companies'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

10%

Debates

0

Incoming

2

Outgoing

8

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AD Kinase Inhibitor Companies

AD Kinase Inhibitor Companies

Overview

Clinical-Stage Programs

Phase 2

Phase 1

Preclinical & Discovery Programs

AD Kinase Inhibitor Companies

Overview

Clinical-Stage Programs

Phase 2

Phase 1

Preclinical & Discovery Programs

Company Profiles

Inhibikase Therapeutics

AB Science

Oligomerix

Alector

Vicore Pharma

Denali Therapeutics

Kinase Targets in Alzheimer's Disease

CDK5 (Cyclin-Dependent Kinase 5)

GSK-3β (Glycogen Synthase Kinase 3 Beta)

RIPK1/3 (Receptor-Interacting Protein Kinase)

Receptor Tyrosine Kinases (KIT, PDGFR, TREM2)

Pipeline Summary

Cross-References

References

💬 Discussion